David Bernstein is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4665 E Galbraith Rd Fl 2
Cincinnati, OH 452362783
Telephone
513-931-0775Provider last certified this registry record 25 Oct 2023.
Clinical trials
- Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea
Sponsor: University of Cincinnati
- An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
Sponsor: Chiesi Farmaceutici S.p.A.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202512 payments
- Stryker CorporationProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
67.7%Histamine-1 Receptor Antagonist26.2%Azelastine Hcl46%Levocetirizine Dihydrochloride28%Diphenhydramine Hcl10%Quzyttir9%Azelastine-Fluticasone7%Part D<11 patientsCorticosteroid24.4%Fluticasone Propionate28%Trelegy Ellipta25%Qvar Redihaler21%Breo Ellipta20%Arnuity Ellipta7%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
18.3%Corticosteroid9.9%Prednisone100%Part D≥35 patientsH2 blocker6.8%Famotidine100%Part D<11 patients+ 1 more class in this area
Nervous system
5.7%Tricyclic Antidepressant4.5%Doxepin Hcl100%Part D<11 patientsGabapentinoids1.2%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
18 NIH research awards on record, funded 1987–2022 per NIH RePORTER. The latest:
18 awards on record per NIH RePORTER; the itemized rows are on their way. Why? →
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”